Rigel Announces Conference Call and Webcast to Report First Quarter 2024 Financial Results and Business Update
Rigel Pharmaceuticals: No Respect With Little Justification, Worth Considering A Buy [Seeking Alpha]
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma [Yahoo! Finance]
Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma